ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Other Events
Item 8.01

As previously disclosed, Adam Grossman, the President and Chief Executive Officer of ADMA Biologics, Inc., a Delaware corporation (the Company), and Brian Lenz, the Companys Executive Vice President and Chief Financial Officer, plan to present at Oppenheimers 29^th Annual Healthcare Conference in New York, NY, on Tuesday, March 19, 2019 at 8:35 AM ET (the Investor Presentation). The Investor Presentation will be webcast live and may be accessed under the Investor Relations tab on the Company’s website at www.admabiologics.com. Additionally, an updated copy of the slides comprising the Investor Presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Please refer to Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risk and uncertainties related thereto.

(d) Exhibits

ADMA BIOLOGICS, INC. Exhibit
…
To view the full exhibit click here

About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.